Pieris is a clinical stage biotechnology company advancing its proprietary Anticalin technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R amp D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. For more information visit www.pieris.com.
Quote | Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)
Last: | $0.19 |
---|---|
Change Percent: | -1.91% |
Open: | $0.186 |
Close: | $0.1937 |
High: | $0.1925 |
Low: | $0.1831 |
Volume: | 329,690 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin ® (antibody-Anticalin fusion) protein immuno-oncolo...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Message Board Posts | Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)
Subject | By | Source | When |
---|---|---|---|
$PIRS .25 -71% | TheFinalCD | investorshub | 06/21/2023 5:41:31 PM |
we got news | rynlrt | investorshub | 06/18/2023 3:53:03 AM |
$PIRS MomentumIts now last up | ttottip | investorshub | 06/16/2023 8:17:29 PM |
are we finally gonna see some action | $oldier Hard | investorshub | 06/14/2023 7:26:42 PM |
$PIRS just the news we needed | $oldier Hard | investorshub | 06/13/2023 9:56:01 PM |
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin ® (antibody-Anticalin fusion) protein immuno-oncolo...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...